Find The Best Stocks With Perfect Trade Setups In Minutes A Day

Stop wasting time looking for the right stocks.  Free training on how to find perfect stock trades that can move 300-1,500%.  Learn the # 1 key to successful stock investing and how to find success even If the market is crashing, rebounding… or just going sideways. (ad)

Do Not Delay - Click Here Now

 

Biotechs Surged This Week – Here Are 2 To Consider Now

These 2 biotech stocks could see double-digit upside over the next year. 

Biotech stocks jumped early this week after pharmaceutical companies delivered positive drug trial results on experimental medicines that could turn into breakthrough treatments for some of the world’s most difficult-to-treat cancers.


Hey, did you know if you really want to retire early, this free training lays it all out for you! Check it out here.


The SPDR S&P Biotech XBI ETF—which tracks the sector’s largest companies—was up as much as 4% between Monday and Wednesday, and the sector has been led this week by cancer drug maker Mirati Therapeutics (NASDAQ: MRTX), which is up just under 39% for the week, as of Friday morning.

Mirati began climbing after Amgen (NASDAQ: AMGN) presented encouraging data on Monday at the 2019 American Society of Clinical Oncology meeting regarding its experimental drug that targets a mutated form of the KRAS gene. 

Researchers found that Amgen’s treatment shrank tumor growth in patients with KRAS mutations—which are believed to cause cancer and are found in some patients with lung, pancreatic, and colorectal cancers—in a small clinical trial of lung cancer patients. The data was seen as a positive for Mirati, a smaller biotech company, as it is also developing drugs that target KRAS mutations.

“We think that Amgen’s phase 1 results should read positive to Mirati’s stock,” said Varun Kumar, an analyst at Cantor Fitzgerald. The analyst said that Amgen’s results “reflect a higher likelihood of a positive readout” from Mirati from its KRAS mutation-blocking drug candidates.

Biotechs have had a difficult last few months along with the broader healthcare sector as concerns have grown around the possibility of Washington lawmakers making significant changes to the U.S. healthcare landscape. Despite this, the XBI Biotech sector ETF is up 13.4% so far this year. 

As for what biotechs look like buys now, Credit Suisse analyst Evan Seigerman likes Vertex Pharmaceuticals (NASDAQ: VRTX), and Neurocrine Biosciences (NASDAQ: NBIX). 

“Among large cap names, we think that Vertex has the best revenue and earnings growth profile,” Seigerman wrote in a note to clients. Seigerman said that while shares look expensive in the short term, the stock looks like a steal over the long term considering the cash flow potential offered by Vertex’s cystic fibrosis treatments and its solid pipeline.

Seigerman also likes Neurocrine Biosciences, a California-based company focused on treatments for endometriosis, and other conditions. “Among our SMid-cap names, Neurocrine is our top pick due to our projected strong revenue growth… namely from Ingrezza,” the company’s dyskinesia drug.

The analyst rates both stocks an Outperform. Seigerman set a price target for Vertex at $209 and for Neurocrine at $95, indicating possible upside of 21% and 16%, respectively, over the next twelve months. 

By the way, if you liked this article, you'll LOVE this Meaty free training I just published on the top 3 questions and challenges every investor faces AND how to overcome them. It's titled "10k into $2.4 Million in 18 months" and you can grab it for free here

There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses. Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Companys software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.

FREE TRADING WEBINAR - TRADERSPRO PRESENTS: Starting With Only $10,000 Retire With $2.4 Million? Click Here Now

Join Us Now
X